This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Jazz (JAZZ) Surges 5.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why Jazz (JAZZ) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises
by Zacks Equity Research
The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adults. The latest nod diversifies its commercial portfolio.
JAZZ or CTLT: Which Is the Better Value Stock Right Now?
by Nilanjan Banerjee
JAZZ vs. CTLT: Which Stock Is the Better Value Option?
JAZZ or CTLT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. CTLT: Which Stock Is the Better Value Option?
Axsome Shares Rise 19% in a Month: What's Driving the Rally?
by Zacks Equity Research
AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while Sunosi diversifies its business.
5 High ROE Stocks to Buy as Volatility Weighs on Markets
by Supriyo Bose
DIS, LDOS, RF, FTNT and JAZZ are some of the stocks with high ROE to profit from as intense volatility spooks markets.
Jazz (JAZZ) Up 3.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wall Street Analysts Think Jazz (JAZZ) Could Surge 44.37%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 44.4% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
ChromaDex (CDXC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.